Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer (Q40944834)

25 September 2017

1 reference

title

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer (English)

1 reference

25 September 2017

Scher HI

1

1 reference

25 September 2017

Zhang ZF

series ordinal

2

1 reference

25 September 2017

Nanus D

series ordinal

3

1 reference

25 September 2017

Kelly WK

series ordinal

4

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

25 September 2017

1 reference

25 September 2017

47

1 reference

25 September 2017

1A Suppl

1 reference

25 September 2017

61-69

1 reference

Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

1 reference

7 January 2021

Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Serum PSA decline after Casodex withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

The human androgen receptor: structure/function relationship in normal and pathological situations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Androgen receptor gene mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Orchidectomy or oestrogen treatment in prostatic cancer: effects on serum levels of adrenal androgens and related steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Androgen receptor gene mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

Adrenal androgen blockade in relapsed prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2896%2980011-2

7 January 2021

10.1016/S0090-4295(96)80011-2

Identifiers

DOI

1 reference

25 September 2017

1 reference